Glutathione S-transferase Pi expression in invasive breast cancer and its relation with the clinical outcome

被引:0
作者
Franco, R. L. [1 ]
Schenka, N. G. M. [2 ]
Schenka, A. A. [2 ]
Rezende, L. F. [1 ]
Gurgel, M. S. C. [1 ]
机构
[1] Univ Estadual Campinas, Dept Obstet & Gynecol, BR-37701316 Campinas, SP, Brazil
[2] Univ Estadual Campinas, Dept Pharmacol, BR-37701316 Campinas, SP, Brazil
来源
JOURNAL OF BUON | 2012年 / 17卷 / 02期
关键词
breast cancer; glutathione S-transferase; immunohistochemistry; prognosis; survival; ADJUVANT CHEMOTHERAPY; PROGNOSTIC-SIGNIFICANCE; THYMIDYLATE SYNTHASE; TRASTUZUMAB;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Glutathione S-transferase (GST) is a cytosolic enzymatic system involved in cellular detoxifying process. In vitro studies have shown that the presence of this enzymatic system in breast carcinoma cells can accelerate the elimination of drugs commonly used in chemotherapy, thereby decreasing its efficacy The aim of the present study was to evaluate the association between GST Pi expression by breast carcinoma cells and disease-free and overall survival. Methods: Ninety-five female patients with invasive breast carcinoma submitted to surgical treatment and adjuvant chemotherapy from January 1995 to June, 1997 and followed until August, 2006 were evaluated. The expression of GST Pi in breast carcinoma cells, determined by immunohistochemistry, was correlated with several clinical and pathological parameters of prognostic significance. Results: There were 36 (37.9%) GST Pi-positive cases. GST Pi immunoexpression was not significantly correlated with patient's age, histological tumor type, clinical stage, hormone receptor status and survival. On the other hand, GST Pi positivity showed a significant correlation with a lower histological grade/C-erb-B2 negative breast carcinoma phenotype. Conclusion: The findings suggest that GST Pi expression does not constitute a satisfactory prognostic factor in breast cancer.
引用
收藏
页码:259 / 264
页数:6
相关论文
共 32 条
  • [1] Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0
  • [2] [Anonymous], NCCN CLIN PRACT GUID
  • [3] Bai F, 1996, CANCER, V78, P416
  • [4] HISTOLOGICAL GRADING AND PROGNOSIS IN BREAST CANCER - A STUDY OF 1409 CASES OF WHICH 359 HAVE BEEN FOLLOWED FOR 15 YEARS
    BLOOM, HJG
    RICHARDSON, WW
    [J]. BRITISH JOURNAL OF CANCER, 1957, 11 (03) : 359 - &
  • [5] Board PG, 1997, BIOCHEM J, V328, P929
  • [6] IMMUNOHISTOCHEMICAL DEMONSTRATION OF GLUTATHIONE S-TRANSFERASES IN PRIMARY HUMAN BREAST CARCINOMAS
    CAIRNS, J
    WRIGHT, C
    CATTAN, AR
    HALL, AG
    CANTWELL, BJ
    HARRIS, AL
    HORNE, CHW
    [J]. JOURNAL OF PATHOLOGY, 1992, 166 (01) : 19 - 25
  • [7] How to improve timing and duration of adjuvant chemotherapy
    Colleoni, M
    Gelber, RD
    Gelber, S
    Castiglione-Gertsch, M
    Coates, AS
    Goldhirsch, A
    [J]. BREAST, 2001, 10 : 101 - 105
  • [8] Elston C W, 2002, Histopathology, V41, P154
  • [9] Fitzgibbons PL, 2000, ARCH PATHOL LAB MED, V124, P966
  • [10] GAMCSIK MP, 1995, CANCER RES, V55, P2012